Literature DB >> 28975885

PET-CT findings in patients with polymyalgia rheumatica without symptoms of cranial ischaemia.

Alexander Lund-Petersen1, Anne Voss, Helle Laustrup.   

Abstract

INTRODUCTION: Polymyalgia rheumatica (PMR) is an inflammatory disorder that affects the elderly. At present, evidence is limited regarding the usefulness of positron emission tomography-computed tomography (PET-CT) in the diagnosis of PMR. This study aimed to compare patient characteristics and symptoms with PET-CT findings in a Danish population of PMR patients without clinical symptoms of giant cell arteritis.
METHODS: The medical records of 50 Danish PET-CT-scanned patients with PMR were reviewed. Symptoms, characteristics and PET-CT findings were registered from the medical records.
RESULTS: Fluorodeoxyglucose (FDG) uptake was seen at the shoulders and/or hips of about 80%, and at the spinous processes of about 50% of the patients. Furthermore, 14% of the patients showed no FDG uptake at any of the studied locations. A sensitivity of 79% for PMR was found if there was FDG uptake at any two of the following three locations: the shoulder, the hip and the spinous processes. Vascular FDG uptake was seen in 7% of the patients. No significant correlations between any symptoms and any PET-CT findings were found. C-reactive protein level was significantly lower in patients receiving glucocorticoids, and completely normal scans were seen significantly more often in patients receiving steroid treatment.
CONCLUSIONS: PET-CT is a sensitive imaging technique in PMR patients. Symptoms and PET-CT findings do not correlate in PMR. Steroid treatment prior to PET-CT reduces the scan's ability to demonstrate inflammation in PMR patients. FUNDING: none. TRIAL REGISTRATION: not relevant. Articles published in the DMJ are “open access”. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28975885

Source DB:  PubMed          Journal:  Dan Med J        ISSN: 2245-1919            Impact factor:   1.240


  3 in total

1.  The Utility of 18F-FDG PET/CT in Patients With Clinical Suspicion of Polymyalgia Rheumatica and Giant Cell Arteritis: A Prospective, Observational, and Cross-sectional Study.

Authors:  Amir Emamifar; Torkell Ellingsen; Søren Hess; Oke Gerke; Rasmus Hviid Larsen; Ziba Ahangarani Farahani; Per Syrak Hansen; Inger Marie Jensen Hansen; Henrik Petersen; Niels Marcussen; Michael Dahlstrøm; Pia Toftegaard; Peter Thye-Rønn
Journal:  ACR Open Rheumatol       Date:  2020-07-22

Review 2.  Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis.

Authors:  K S M van der Geest; G Treglia; A W J M Glaudemans; E Brouwer; F Jamar; R H J A Slart; O Gheysens
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-12-28       Impact factor: 9.236

3.  Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica.

Authors:  Kornelis S M van der Geest; Yannick van Sleen; Pieter Nienhuis; Maria Sandovici; Nynke Westerdijk; Andor W J M Glaudemans; Elisabeth Brouwer; Riemer H J A Slart
Journal:  Rheumatology (Oxford)       Date:  2022-03-02       Impact factor: 7.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.